Dear Alliance,

It’s only a 13 days until October 5th and we hope you share our excitement about the Alliance Vision meeting.

We had a prep session for the break-out section leaders that went very well. We intend to produce a 1-slide summary with each of the 8 focus-groups.

We will try to assign you to the group of your choice (if possible). Just follow the link to the registration and you can select which focus group you like best.

In addition, we had a call with the speakers and coordinated the content of the talks.

All the speakers are very excited and the content align very nice. We will have contributions from MDIC, FDA, DPA, and Friends of Cancer Research (https://www.foer.org/). I’d like to specifically thank the leadership of these organizations and their representatives for contributing to this meeting.

It is a first sign that the collaborative environment can get things accomplished.

We are in particular excited to specifically account for the patient perspective. Please take a look at the agenda.

The key element that you can do to move digital pathology forward, is to propose a project.

These project proposals will be presented to MDIC, which means numerous device manufacturers and vendors in the industry will take a look.

That’s a very unique opportunity to establish collaborations and potentially obtain funding. We are soliciting very straightforward 1-page project proposals. Project proposal blueprints can be found here: https://digitalpathologyalliance.org/s/Alliance-Project-Proposal-Blueprint.docx

Take a look at the blueprints. We would very much appreciate it.

The venue for the meeting is here


and if you haven’t registered – please do so here for free:
https://digitalpathologyalliance.org/

If you have questions – please do not hesitate to let us know.

With kind regards,

The Alliance Steering Committee

Joe Lennerz, MGH
Esther Abels, DPA, PathAI
Brandon Gallas, FDA
Jithesh Veetil, MDIC
Scott Blakely, DPA, Hamamatsu
Sarah Dudgeon, FDA
Matthew G. Hanna, MSKCC
Richard Huang, MGH
Amanda Lowe, Visiopharm
Hetal Marble, MGH
Ashish Sharma, Emory